SESSION TITLE: DVT/PE/Pulmonary Hypertension Posters
SESSION TYPE: Original Investigation Poster
PRESENTED ON: Wednesday, October 30, 2013 at 01:30 PM - 02:30 PM
PURPOSE: To assess clinical characteristics and survival of persons diagnosed with pulmonary hypertension (PAH) between 2005 and 2011 years.
METHODS: From the Yedikule Chest Diseases and Thoracic Surgery Training and Investigation Hospital database between 2005-2011 years 18 PAH patients were identified. In the stage of diagnosis, blood count, biochemistry, radiology, pulmonary function tests, ECHO, ProBnP, cardiopulmonary hemodynamics retrospectively analyzed. According to New York Heart Association Functional Classification (NYHA) and 6-min walk distance (6MWD) the functional assessment of participation were retrospectively analyzed. Data analysis performed using number, percentage, mean, standart deviation, minimum, maximum. Survival analysis was performed using the Kaplan-Meier method.
RESULTS: The mean ages of patients with PAH were 56.62±14,97. 12 (66.7%) were female. The estimated mean survival was 2.83±0.13 years. One of patients had a family history. 7 (38.9%) were diagnosed with IPAH, 6 (33.3%) with scleroderma and PAH, 3(16.7%) with chronic thromboembolic pulmonary hypertension (CTEPH), 1 (5.6%) with idiopathic pulmonary fibrosis (IPF) and PAH, 1 (5.6%) with PAH. The mean ProBnP of patients were 575.9±504. Eight patients were given calcum channel blokers, eight patients were given bosentan and two patients were given bosentan and inhaler iloprost. Eight patients died during treatment. (One patient whiles the planning of surgical treatment, the three patients had the scleroderma and PAH, the two patients had the IPAH, and the one patient had the IPF and PAH).
CONCLUSIONS: Mortality in PAH is largely associated with hemodynamic variables that assess right ventricular function. A relatively low specificity to predict survival in our PAH population. In the diagnosis and following phase of collagen tissue illness and the chronic thromboembolism can be seen PAH.
CLINICAL IMPLICATIONS: Multicenter trial is needed to evaluate the survival and prognostic factor in all patients with PAH in Turkey. In conclusion, in the diagnosis and following phase of collagen tissue illness and the chronic thromboembolism can be seen PAH. Patients with PAH have poor survival expectancy and in this limited study with a small number of patients.
DISCLOSURE: The following authors have nothing to disclose: Safiye Özkan
No Product/Research Disclosure Information